# Title

 Food and Drugs. PART 330â€”OVER-THE-COUNTER (OTC) HUMAN DRUGS WHICH ARE GENERALLY RECOGNIZED AS SAFE AND EFFECTIVE AND NOT MISBRANDED


# ID

 CFR-2018-title21-vol5.Pt. 330


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['minimum of', 'maximum', 'more than', 'no later than', 'before', 'after', 'prior to', 'minimum', 'less than', 'at least', 'within', 'exceed']                                                                                                                                                                                                                                                                                                                                 |
| Duration    | ['30 day', '912.0 day', '90.0 day', '12.0 month', '180.0 day', '60.0 day', '5.0 year', '730.0 day', '30.0 day', '120.0 day', '1095.0 day']                                                                                                                                                                                                                                                                                                                                     |
| Condition   | ['subject to', 'until', 'where', 'not subject to', 'when', 'unless', 'if']                                                                                                                                                                                                                                                                                                                                                                                                     |
| Entities    | ['Nervousness', 'Food', 'Data', 'Powder', 'Worsen', 'U.S', 'Provide', 'Information', 'Safety', 'Isolated', 'Clean', 'Avoid', 'Indications', 'Aggravate', 'Improve', 'English', 'Color', 'Rockville, MD', 'United States', 'U.S. Pharmacopeia', 'Medication', 'Prompt', 'Tends', 'Indication', 'Tend', 'Develop', 'Certain', 'Produce', 'Continue', 'Individual', 'Thirty', 'Use', 'Miscellaneous', 'New', 'Obtain', 'Drug']                                                    |
| Date        | ['1971-02-18', '1970-07-03', '2014-11-27', '1970-10-08', '1971-05-25', '1981-02-01', '1973-03-09', '1972-11-29', '1970-10-17', '1971-10-28', '1973-03-15', '1972-02-01', '2018-03-01', '1971-10-09', '1972-05-11', '1971-07-14', '1971-08-28', '1970-10-24', '1972-03-14', '1981-07-27', '1972-07-06', '1967-02-02', '1971-11-11', '1972-09-30', '1969-12-31', '1971-08-06', '1973-02-02', '1971-04-09', '1972-11-19', '1972-12-05', '1972-04-20', '1970-07-23', '1975-12-04'] |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                       |
|:--------------|:------------------------------------------------------------------------------------------------------------------------------|
| more than     | used topically and intended for oral use, &#8220;If more than used for&#8221; (insert intended use, e.g., pain) &#8220;is     |
| maximum       | (h) Where no  maximum daily dosage limit for an active ingredient is                                                          |
| exceed        | a product at a level that does not exceed the amount reasonably required to achieve its intended                              |
| before        | first consulting your doctor&#8221; or &#8220;consult your doctor before &#8221;.                                             |
| exceed        | &#8220;Exceed recommended dosage&#8221; or &#8220;use more than directed&#8221;. exceed                                       |
| more than     | (29) &#8220;Exceed recommended dosage&#8221; or &#8220;use  more than  directed&#8221;.                                       |
| before        | (20) &#8220;While taking this product&#8221; or &#8220; before  taking this product&#8221;.                                   |
| within        | (z) Miscellaneous (all other OTC drugs not falling  within  one of the above therapeutic categories).                         |
| within        | submitted pursuant to a published notice, and falling within the confidentiality provisions of 18 U.S.C. 1905, 5              |
| within        | person submitting it demonstrates that it still falls within the confidentiality provisions of one or more of                 |
| within        | the data and/or views on any marketed drug within the class must be submitted, preferably bound, indexed,                     |
| within        | forth in paragraph (a)(2) of this section and within the time period established for the drug category                        |
| within        | to the conditions under which OTC drugs falling within the category covered by the panel are generally                        |
| within        | Included  within  this report shall be:                                                                                       |
| within        | of further testing required and the time period within  which it might reasonably be concluded.                               |
| after         | safe and effective and not misbranded (Category I). after                                                                     |
| within        | order shall specify a reasonable period of time within  which conditions falling                                              |
| within        | order shall specify a reasonable period of time within  which conditions falling                                              |
| within        | Any interested person may,  within 90 days after publication of the proposed order                                            |
| after         | Any interested person may, within 90 days  after publication of the proposed order in the Federal                             |
| after         | Within 30 days  after the final day for submission of comments, reply                                                         |
| before        | conclusions and recommendations, to obtain full public comment before undertaking his own evaluation and decision on the      |
| after         | and any new data and information or, alternatively, after reviewing a panel's recommendations, the Commissioner shall publish |
| after         | and any new data and information or, alternatively, after reviewing a panel's recommendations, the Commissioner shall publish |
| within        | specifying with particularity the omissions or additions requested. within                                                    |
| within        | the tentative order to which objection is made. within                                                                        |
| within        | excluded from the monograph in the tentative order. within                                                                    |
| after         | (iii) Within 12 months  after publishing a tentative order pursuant to paragraph (a)(7)(i)                                    |
| within        | Division of Dockets Management, Food and Drug Administration. within                                                          |
| after         | (iv) Within 60 days  after the final day for submission of new data                                                           |
| after         | (v) New data and information submitted  after the time specified in this paragraph but prior                                  |
| prior to      | after the time specified in this paragraph but prior to the establishment of a final monograph will be                        |
| after         | (v) New data and information submitted  after the time specified in this paragraph but prior                                  |
| before        | (8) Oral hearing  before  the Commissioner.                                                                                   |
| after         | in the Federal Register schedule an oral hearing. after                                                                       |
| after         | recognized as safe and effective and not misbranded. after                                                                    |
| within        | Any interested person may,  within 90 days after publication of the proposed order                                            |
| after         | Any interested person may, within 90 days  after publication of the proposed order in the Federal                             |
| after         | proposal if comments opposing the amendment are persuasive. after                                                             |
| prior to      | condition for which approval is sought is undertaken prior to  approval of the new drug application.                          |
| after         | which fails to conform to an applicable monograph after  its effective date is liable to regulatory action.                   |
| after         | Information and data submitted under this section  after July 27, 1981, shall include statements regarding each               |
| after         | (b) On and  after April 20, 1972, a number of notices were                                                                    |
| less than     | new drug applications, updating supplements, data to support less than effective claims, if any, etc., are deferred, and      |
| prior to      | Register of February 2, 1967 (32 FR 1172) prior to  the drug efficacy study implementation.                                   |
| before        | limitation pursuant to &#167;&#8201;310.200 of this chapter, or before                                                        |
| after         | contains: (1) An active ingredient limited, on or after May 11, 1972, to prescription use for the                             |
| after         | contains: (1) An active ingredient limited, on or after May 11, 1972, to prescription use for the                             |
| within        | 1975, shall be regarded as a new drug within the meaning of section 201(p) of the act                                         |
| after         | contains: (i) An active ingredient limited, on or after May 11, 1972, to prescription use for the                             |
| after         | contains: (i) An active ingredient limited, on or after May 11, 1972, to prescription use for the                             |
| within        | &#167;&#8201;330.10(a)(6)(i)) shall be regarded as a new drug within the meaning of section 201(p) of the act                 |
| prior to      | application is required if marketed for OTC use prior to the date of publication in the Federal Register                      |
| after         | paragraph (b)(1) of this section which is marketed after the date of publication in the Federal Register                      |
| prior to      | the Federal Register of a proposed monograph but prior to the effective date of a final monograph shall                       |
| after         | contains: (1) An active ingredient limited, on or after May 11, 1972, to prescription use for the                             |
| after         | contains: (1) An active ingredient limited, on or after May 11, 1972, to prescription use for the                             |
| after         | contains: (1) An active ingredient limited, on or after May 11, 1972, to prescription use for the                             |
| after         | contains: (1) An active ingredient limited, on or after May 11, 1972, to prescription use for the                             |
| after         | (OTC) drugs initially marketed in the United States after the OTC drug review began in 1972 and                               |
| no later than | the submission over protest (this date will be no later than 30 days after the request that FDA file                          |
| after         | date will be no later than 30 days after the request that FDA file the submission over                                        |
| minimum of    | condition must have been marketed OTC for a minimum of 5 continuous years in the same country and                             |
| more than     | with 5 continuous years of marketing, marketing in more than  one country may be necessary.                                   |
| minimum of    | OTC in 5 or more countries with a minimum of 5 continuous years of marketing in at least                                      |
| at least      | minimum of 5 continuous years of marketing in at least one country, the sponsor may submit information in                     |
| minimum       | Provide an estimate of the  minimum number of potential consumer exposures to the condition                                   |
| minimum of    | OTC in five or more countries with a minimum of 5 continuous years of marketing in at least                                   |
| at least      | minimum of 5 continuous years of marketing in at least  one country, the sponsor may select                                   |
| at least      | minimum of 5 continuous years of marketing in at least  one country, the sponsor may select                                   |
| minimum of    | Selected countries must include the country with a  minimum of 5 continuous years of OTC marketing, countries that            |
| more than     | Sponsors should provide information from  more than five countries if they believe that it is                                 |
| more than     | For OTC drugs that have been marketed for more than 5 years in the United States under a                                      |
| after         | public display in the Division of Dockets Management after deletion of information deemed confidential under 18 U.S.C.        |
| after         | with an applicable final OTC drug monograph(s) only after the agency determines that the condition is generally               |
| after         | not been finalized and finalization is not imminent, after the agency has evaluated the comments to a                         |
| prior to      | subject to the risk that the agency may, prior to or in the final monograph, adopt a different                                |
| after         | will determine whether the submission may be filed. after                                                                     |
| after         | Data submitted  after the date of filing will be considered before                                                            |
| before        | after the date of filing will be considered before the issuance of a notice of proposed rulemaking                            |
| after         | Data submitted  after the date of filing will be considered before                                                            |
| within        | The submitter may request in writing,  within 30 days of the date of the agency's                                             |
| within        | The submitter may request in writing,  within 30 days of the date of the agency's                                             |
| within        | If,  within 120 days after the meeting, the submitter requests                                                                |
| after         | If, within 120 days  after the meeting, the submitter requests that FDA file                                                  |
| before        | The submitter must have a meeting  before requesting that FDA file the submission over protest                                |
| before        | will notify the person that submitted the submission. before                                                                  |
| within        | If,  within 90 days from the date of the notice                                                                               |
| before        | a TEA submission that is withdrawn from consideration before issuance of a notice of eligibility, in which                    |
| before        | such ingredients submitted in a TEA under &#167;&#8201;330.14 before November 27, 2014, subject to section 586F(a)(1)(C) of   |
| within        | percent of eligibility notices or ineligibility letters issued within 180 days of submission of a TEA; (2)                    |
| within        | percent of eligibility notices or ineligibility letters issued within 180 days of submission of a TEA; (2)                    |
| within        | percent of eligibility notices or ineligibility letters issued within 180 days of submission of a TEA; (2)                    |
| within        | percent of eligibility notices or ineligibility letters issued within 180 days of submission of a TEA; (2)                    |
| within        | percent of eligibility notices or ineligibility letters issued within 180 days of submission of a TEA; (2)                    |
| within        | FDA will review and take an action  within the following timelines: (1) Within 180 days of                                    |
| within        | FDA will review and take an action  within the following timelines: (1) Within 180 days of                                    |
| within        | with &#167;&#8201;330.14(j), FDA will issue a filing determination. within                                                    |
| within        | determination by feedback letter in accordance with &#167;&#8201;330.14(g)(4). within                                         |
| within        | Include the condition in &#167;&#8201;310.502 of this chapter. within                                                         |
| within        | this section, FDA will issue a final rule. within                                                                             |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-----------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 30 day     | Thirty days thereafter such data and information shall be made publicly available and may be viewed at the office of the Division of Dockets Management of the Food and Drug Administration, except to the extent that the person submitting it demonstrates that it still falls within the confidentiality provisions of one or more of those statutes.                                                                                                                                                                                                                                                                                                                                                                                                          |
| 90.0 day   | Any interested person may, within 90 days after publication of the proposed order in the Federal Register, file with the Division of Dockets Management of the Food and Drug Administration written comments in triplicate.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 30.0 day   | Within 30 days after the final day for submission of comments, reply comments may be filed with the Division of Dockets Management; these comments shall be utilized to reply to comments made by other interested persons and not to reiterate a position.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 90.0 day   | Within 90 days, any interested person may file with the Division of Dockets Management, Food and Drug Administration, written comments or written objections specifying with particularity the omissions or additions requested.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 90.0 day   | Within 90 days, any interested person may file with the Division of Dockets Management, Food and Drug Administration, written objections specifying with particularity the provision of the tentative order to which objection is made.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 12.0 month | (iii) Within 12 months after publishing a tentative order pursuant to paragraph (a)(7)(i) of this section, any interested person may file with the Division of Dockets Management, Food and Drug Administration, new data and information to support a condition excluded from the monograph in the tentative order.                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 60.0 day   | (iv) Within 60 days after the final day for submission of new data and information, comments on the new data and information may be filed with the Division of Dockets Management, Food and Drug Administration.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 90.0 day   | (i) All data and information to be considered in any proceeding pursuant to this section shall be submitted in response to the request for data and views pursuant to paragraph (a)(2) of this section, in response to any other notice published in the Federal Register, or accepted by the panel during its deliberations pursuant to paragraph (a)(3) of this section or submitted to the Division of Dockets Management as part of the comments during the 90-day period and 30-day rebuttal comment period permitted pursuant to paragraph (a)(6) of this section or submitted to the Division of Dockets Management during the 12-month period or as part of the comments during the 60-day period permitted pursuant to paragraph (a)(7) of this section. |
| 30.0 day   | (i) All data and information to be considered in any proceeding pursuant to this section shall be submitted in response to the request for data and views pursuant to paragraph (a)(2) of this section, in response to any other notice published in the Federal Register, or accepted by the panel during its deliberations pursuant to paragraph (a)(3) of this section or submitted to the Division of Dockets Management as part of the comments during the 90-day period and 30-day rebuttal comment period permitted pursuant to paragraph (a)(6) of this section or submitted to the Division of Dockets Management during the 12-month period or as part of the comments during the 60-day period permitted pursuant to paragraph (a)(7) of this section. |
| 12.0 month | (i) All data and information to be considered in any proceeding pursuant to this section shall be submitted in response to the request for data and views pursuant to paragraph (a)(2) of this section, in response to any other notice published in the Federal Register, or accepted by the panel during its deliberations pursuant to paragraph (a)(3) of this section or submitted to the Division of Dockets Management as part of the comments during the 90-day period and 30-day rebuttal comment period permitted pursuant to paragraph (a)(6) of this section or submitted to the Division of Dockets Management during the 12-month period or as part of the comments during the 60-day period permitted pursuant to paragraph (a)(7) of this section. |
| 60.0 day   | (i) All data and information to be considered in any proceeding pursuant to this section shall be submitted in response to the request for data and views pursuant to paragraph (a)(2) of this section, in response to any other notice published in the Federal Register, or accepted by the panel during its deliberations pursuant to paragraph (a)(3) of this section or submitted to the Division of Dockets Management as part of the comments during the 90-day period and 30-day rebuttal comment period permitted pursuant to paragraph (a)(6) of this section or submitted to the Division of Dockets Management during the 12-month period or as part of the comments during the 60-day period permitted pursuant to paragraph (a)(7) of this section. |
| 90.0 day   | Any interested person may, within 90 days after publication of the proposed order in the Federal Register, file with the Division of Dockets Management, Food and Drug Administration, written comments in triplicate.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 30.0 day   | (3) Date of filing means the date of the notice from FDA stating that FDA has made a threshold determination that the safety and effectiveness data submission is sufficiently complete to permit a substantive review; or, if the submission is filed over protest in accordance with paragraph (j)(3) of this section, the date of filing is the date of the notice from FDA stating that FDA has filed the submission over protest (this date will be no later than 30 days after the request that FDA file the submission over protest).                                                                                                                                                                                                                      |
| 5.0 year   | (8) For OTC drugs that have been marketed for more than 5 years in the United States under a new drug application, the information requested in paragraphs (c)(2)(i), (c)(2)(iii), (c)(2)(v), (c)(3), and (c)(5) of this section need not be provided.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 30.0 day   | The submitter may request in writing, within 30 days of the date of the agency's notification, a meeting with the agency about whether the agency should file the submission, and FDA will convene the meeting within 30 days of the request.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 30.0 day   | The submitter may request in writing, within 30 days of the date of the agency's notification, a meeting with the agency about whether the agency should file the submission, and FDA will convene the meeting within 30 days of the request.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 120.0 day  | If, within 120 days after the meeting, the submitter requests that FDA file the submission (with or without correcting the deficiencies), the agency will file the safety and effectiveness data submission over protest under paragraph (j)(2) of this section, notify the submitter in writing and post a copy to the docket, and review the submission as filed.                                                                                                                                                                                                                                                                                                                                                                                               |
| 90.0 day   | If, within 90 days from the date of the notice from FDA, the submitter requests that FDA not withdraw consideration of the submission, FDA will not deem the submission to be withdrawn.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 180.0 day  | (1) Number and percent of eligibility notices or ineligibility letters issued within 180 days of submission of a TEA;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (2) Number and percent of filing determinations issued within 90 days of submission of a safety and effectiveness data submission;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (3) If applicable, number and percent of feedback letters issued within 730 days from the date of filing;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (4) Number and percent of notices for proposed rulemaking issued within 1,095 days from the date of filing;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (5) Number and percent of final rules issued within 912 days of closing of the docket of the proposed rulemaking; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (6) Total number of TEAs submitted under &#167;&#8201;330.14.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 90.0 day   | (1) Number and percent of eligibility notices or ineligibility letters issued within 180 days of submission of a TEA;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (2) Number and percent of filing determinations issued within 90 days of submission of a safety and effectiveness data submission;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (3) If applicable, number and percent of feedback letters issued within 730 days from the date of filing;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (4) Number and percent of notices for proposed rulemaking issued within 1,095 days from the date of filing;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (5) Number and percent of final rules issued within 912 days of closing of the docket of the proposed rulemaking; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (6) Total number of TEAs submitted under &#167;&#8201;330.14.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 730.0 day  | (1) Number and percent of eligibility notices or ineligibility letters issued within 180 days of submission of a TEA;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (2) Number and percent of filing determinations issued within 90 days of submission of a safety and effectiveness data submission;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (3) If applicable, number and percent of feedback letters issued within 730 days from the date of filing;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (4) Number and percent of notices for proposed rulemaking issued within 1,095 days from the date of filing;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (5) Number and percent of final rules issued within 912 days of closing of the docket of the proposed rulemaking; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (6) Total number of TEAs submitted under &#167;&#8201;330.14.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1095.0 day | (1) Number and percent of eligibility notices or ineligibility letters issued within 180 days of submission of a TEA;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (2) Number and percent of filing determinations issued within 90 days of submission of a safety and effectiveness data submission;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (3) If applicable, number and percent of feedback letters issued within 730 days from the date of filing;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (4) Number and percent of notices for proposed rulemaking issued within 1,095 days from the date of filing;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (5) Number and percent of final rules issued within 912 days of closing of the docket of the proposed rulemaking; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (6) Total number of TEAs submitted under &#167;&#8201;330.14.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 912.0 day  | (1) Number and percent of eligibility notices or ineligibility letters issued within 180 days of submission of a TEA;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (2) Number and percent of filing determinations issued within 90 days of submission of a safety and effectiveness data submission;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (3) If applicable, number and percent of feedback letters issued within 730 days from the date of filing;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (4) Number and percent of notices for proposed rulemaking issued within 1,095 days from the date of filing;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (5) Number and percent of final rules issued within 912 days of closing of the docket of the proposed rulemaking; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (6) Total number of TEAs submitted under &#167;&#8201;330.14.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 180.0 day  | FDA will review and take an action within the following timelines:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (1) Within 180 days of submission of a TEA under &#167;&#8201;330.14(c), FDA will issue a notice of eligibility or post to the docket a letter of ineligibility, in accordance with &#167;&#8201;330.14(d) and (e).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 90.0 day   | (2) Within 90 days of submission of a safety and effectiveness data submission, in accordance with &#167;&#8201;330.14(j), FDA will issue a filing determination.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 730.0 day  | (3) Within 730 days from the date of filing, if the condition is initially determined not to be GRASE for OTC use in the United States, FDA will inform the sponsor and other interested persons who have submitted data of its determination by feedback letter in accordance with &#167;&#8201;330.14(g)(4).                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1095.0 day | (4) Within 1,095 days from the date of filing of a safety and effectiveness data submission, FDA will issue a notice of proposed rulemaking to either:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (i) Include the condition in an appropriate OTC monograph(s), either by amending an existing monograph(s) or establishing a new monograph(s), if necessary; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (ii) Include the condition in &#167;&#8201;310.502 of this chapter.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 912.0 day  | (5) Within 912 days of the closing of the docket of the proposed rulemaking under paragraph (c)(4) of this section, FDA will issue a final rule.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |


## Condition

| Condition      | Context                                                                                                                                       |
|:---------------|:----------------------------------------------------------------------------------------------------------------------------------------------|
| if             | as safe and effective and is not misbranded if it meets each of the conditions contained in                                                   |
| subject to     | subchapter C, including &#167;&#8201;201.66 of this chapter, is subject to  regulatory action.                                                |
| subject to     | that have been established in an applicable monograph, subject to the provisions of section 502 of the act                                    |
| where          | chapter shall be stated in the exact language where exact language has been established and identified by                                     |
| if             | or with suitable tests or assays to determine if the product meets its professed standards of identity,                                       |
| where          | will grant an exemption from these general warnings where appropriate upon petition, which shall be maintained in                             |
| where          | amount reasonably required to achieve its intended effect. where                                                                              |
| until          | and the Food and Drug Administration as confidential until publication of a proposed monograph and the full                                   |
| until          | and the Food and Drug Administration as confidential until publication of a proposed monograph and the full                                   |
| when           | target population, the pharmacological effect of the drug, when used under adequate directions for use and warnings                           |
| unless         | investigations as defined in &#167;&#8201;314.126(b) of this chapter, unless this requirement is waived on the basis of                       |
| when           | may be generally recognized as safe and effective when each active ingredient makes a contribution to the                                     |
| when           | may be generally recognized as safe and effective when each active ingredient makes a contribution to the                                     |
| when           | may be generally recognized as safe and effective when each active ingredient makes a contribution to the                                     |
| when           | may be generally recognized as safe and effective when each active ingredient makes a contribution to the                                     |
| unless         | for OTC sale and use by the laity unless , because of its toxicity or other potential                                                         |
| when           | This order may be published  when no substantive comments in opposition to the panel                                                          |
| when           | This order may be published  when no substantive comments in opposition to the panel                                                          |
| unless         | monograph has been published in the Federal Register unless the Commisisoner finds that good cause has been                                   |
| if             | response to the tentative final monograph, the Commissioner, if he finds reasonable grounds in support thereof, shall                         |
| if             | The Commissioner may deny the petition  if the Commissioner finds a lack of safety or                                                         |
| if             | The Commissioner may deny the petition  if the Commissioner finds a lack of safety or                                                         |
| if             | (a)(9) of this section or withdraw the proposal if  comments opposing the amendment are persuasive.                                           |
| if             | petition to amend the OTC drug monograh only if the drug product with the condition that is                                                   |
| if             | monograph, and shall review it on that basis, if the provisions of this paragraph preclude approval of                                        |
| if             | forth in part 58 of this chapter, or, if the study was not conducted in compliance with                                                       |
| not subject to | in part 56 of this chapter, or was not subject to such requirements in accordance with &#167;&#167;&#8201;56.104 or 56.105,                   |
| if             | supplements, data to support less than effective claims, if any, etc., are deferred, and such OTC drug                                        |
| subject to     | deferred, and such OTC drug products are instead subject to the OTC drug review in their appropriate classes                                  |
| when           | (2) Deferral of requirements is not appropriate  when an announcement has been published and has been                                         |
| if             | These products will be removed from the market,  if  they have not already been removed.                                                      |
| if             | the act as a result of the changes if the changes in formulation and/or labeling are of                                                       |
| subject to     | classified by the panel in category I (conditions subject to &#167;&#8201;330.10(a)(6)(i)) shall be regarded as a new drug                    |
| if             | 1975, which ingredient and/or dosage level is class if ied by the panel in category I (conditions                                             |
| subject to     | effective date of a final monograph shall be subject to the risk that the Commissioner may not accept                                         |
| subject to     | classified by the panel in category II (conditions subject to  &#167;&#8201;330.10(a)(6)(ii)), may be marketed only after:                    |
| subject to     | classified by the panel in category III (conditions subject to  &#167;&#8201;330.10(a)(6)(iii)), may be marketed only after:                  |
| if             | sufficiently complete to permit a substantive review; or, if the submission is filed over protest in accordance                               |
| when           | Certain information must be provided  when requesting that a condition subject to this section                                                |
| subject to     | must be provided when requesting that a condition subject to this section be considered for inclusion in the                                  |
| if             | each country and explain why there are d if ferences or changes.                                                                              |
| if             | A description of the country's system for ident if ying adverse drug experiences, especially those found in                                   |
| where          | approved by a regulatory body in each country where  the condition is marketed.                                                               |
| if             | should provide information from more than five countries if they believe that it is needed to support                                         |
| where          | (5) A list of all countries  where the condition is marketed only as a prescription                                                           |
| until          | Drug Administration will handle the TEA as confidential until such time as a decision is made on                                              |
| subject to     | and other information submitted under this paragraph are subject to  the requirements in &#167;&#8201;330.10(c), (e), and (f).                |
| where          | and 314.80 of this chapter, from each country where the condition has been or is currently marketed                                           |
| if             | by a report under the provisions of &#167;&#8201;330.10(a)(5). if                                                                             |
| if             | an existing monograph(s) or establishing a new monograph(s), if  necessary.                                                                   |
| if             | an existing monograph(s) or establishing a new monograph(s), if  necessary.                                                                   |
| if             | docket established in the Division of Dockets Management. if                                                                                  |
| if             | will subsequently publish a final rule (or reproposal if  necessary) in the Federal Register.                                                 |
| subject to     | to begin pending completion of the final monograph subject to the risk that the agency may, prior to                                          |
| if             | the agency will file the submission and not if y the submitter in writing.                                                                    |
| if             | the issuance of a notice of proposed rulemaking if there is adequate time for review; otherwise, the                                          |
| if             | and effectiveness data submission, the agency will not if y the submitter in writing and state the                                            |
| if             | TEA-eligible condition are both not deemed under consideration if FDA refuses to file the safety and effectiveness                            |
| if             | to file a safety and effectiveness data submission if any of the following applies: (i) The submission                                        |
| subject to     | information to establish that the requested action is subject to categorical exclusion under &#167;&#8201;25.30 or &#167;&#8201;25.31 of this |
| if             | forth in part 58 of this chapter, or, if it was not conducted in compliance with part                                                         |
| not subject to | in part 56 of this chapter, or was not subject to those regulations, and that the investigation was conducted                                 |
| if             | withdrawal will only be provided to the sponsor. if                                                                                           |
| if             | not be included in the metrics under &#167;&#8201;330.15(b). if                                                                               |
| subject to     | a TEA under &#167;&#8201;330.14 before November 27, 2014, subject to section 586F(a)(1)(C) of the Federal Food, Drug, and                     |
| subject to     | and safety and effectiveness data submissions that are subject to  the timelines in this section.                                             |
| if             | (6) Total number of TEAs submitted under &#167;&#8201;330.14. if                                                                              |
| if             | Within 730 days from the date of filing, if the condition is initially determined not to be                                                   |
| if             | an existing monograph(s) or establishing a new monograph(s), if necessary; or (ii) Include the condition in &#167;&#8201;310.502              |


## Entities

| Entities          | Context                                                                                                                        |
|:------------------|:-------------------------------------------------------------------------------------------------------------------------------|
| Food              | Food  and Drugs.                                                                                                               |
| Indications       | product shall contain the labeling describing the &#8220; Indications &#8221; that have been established in an applicable      |
| Color             | Color additives may be used only in accordance with                                                                            |
| Rockville, MD     | 1061,  Rockville, MD  20852.                                                                                                   |
| Aggravate         | (3) &#8220; Aggravate (s)&#8221; or &#8220;make(s) worse&#8221;.                                                               |
| Avoid             | (10) &#8220; Avoid contact with eyes&#8221; or &#8220;do not get into                                                          |
| Clean             | (14) &#8220; Clean &#8221; or &#8220;cleanse&#8221;.                                                                           |
| Continue          | (16) &#8220; Continue (s)&#8221; or &#8220;persist(s)&#8221; or &#8220;is persistent&#8221; or &#8220;do(es)                   |
| Develop           | (18) &#8220; Develop (s)&#8221; or &#8220;begin(s)&#8221; or &#8220;occur(s)&#8221;.                                           |
| Improve           | (42) &#8220; Improve (s)&#8221; or &#8220;get(s) better&#8221; or &#8220;make(s) better&#8221;.                                |
| Indication        | (45) &#8220; Indication (s)&#8221; or &#8220;Use(s)&#8221;.                                                                    |
| Use               | (45) &#8220;Indication(s)&#8221; or &#8220; Use (s)&#8221;.                                                                    |
| Medication        | (52) &#8220; Medication (s)&#8221; or &#8220;medicine(s)&#8221; or &#8220;drug(s)&#8221;.                                      |
| Nervousness       | (53) &#8220; Nervousness , dizziness, or sleeplessness occurs&#8221; or &#8220;you get                                         |
| Obtain            | (55) &#8220; Obtain (s)&#8221; or &#8220;get(s)&#8221;.                                                                        |
| Produce           | (61) &#8220; Produce (s)&#8221; or &#8220;cause(s)&#8221;.                                                                     |
| Prompt            | (62) &#8220; Prompt (ly)&#8221; or &#8220;quick(ly)&#8221; or &#8220;right away&#8221;.                                        |
| Tend              | (69) &#8220; Tend (s) to recur&#8221; or &#8220;reoccur(s)&#8221; or &#8220;return(s)&#8221; or                                |
| Worsen            | (79) &#8220; Worsen (s)&#8221; or &#8220;get(s) worse&#8221; or &#8220;make(s) worse&#8221;.                                   |
| Tends             | (17) &#8220; Tends  to&#8221;.                                                                                                 |
| Drug              | Drug  categories.                                                                                                              |
| Miscellaneous     | (z)  Miscellaneous (all other OTC drugs not falling within one                                                                 |
| Data              | Data and information submitted pursuant to a published notice,                                                                 |
| Thirty            | Thirty days thereafter such data and information shall be                                                                      |
| Isolated          | Isolated case reports, random experience, and reports lacking the                                                              |
| New               | (v)  New data and information submitted after the time specified                                                               |
| Information       | Information and data submitted under this section after July                                                                   |
| Food              | published, with no conclusions of the Commissioner of Food  and Drugs.                                                         |
| Powder            | (ii) Absorbable Dusting  Powder (DESI 6264), published in the Federal Register of                                              |
| Certain           | (i)  Certain Sulfonamide-Decongestant Nasal Preparation (DESI 4850), for which notice                                          |
| Certain           | (xiii)  Certain Sulfonamide-Containing Preparations for Topical Ophthalmic or Otic Use                                         |
| United States     | which over-the-counter (OTC) drugs initially marketed in the United States after the OTC drug review began in 1972             |
| U.S               | began in 1972 and OTC drugs without any U.S . marketing experience can be considered in the                                    |
| United States     | would be regulated as OTC drugs in the United States .                                                                         |
| Certain           | Certain information must be provided when requesting that a                                                                    |
| U.S. Pharmacopeia | (iii) Reference to the current edition of the  U.S. Pharmacopeia (USP)-National Formulary (NF) or foreign compendiums may help |
| U.S               | condition's use(s) can be reasonably extrapolated to the U.S . population.                                                     |
| English           | All labeling that is not in  English  must be translated to                                                                    |
| United States     | marketed for more than 5 years in the United States under a new drug application, the information requested                    |
| Rockville, MD     | 1061,  Rockville, MD  20852.                                                                                                   |
| Safety            | Safety and effectiveness data and other information submitted under                                                            |
| Provide           | Provide individual adverse drug experience reports (FDA Form 3500A                                                             |
| Individual        | Individual reports that are not in English must be                                                                             |
| English           | Individual reports that are not in  English  must be translated to                                                             |
| United States     | safe and effective for OTC use in the United States , the agency will propose to include it                                    |
| United States     | to be GRASE for OTC use in the United States , the agency will inform the sponsor and                                          |
| United States     | to be GRASE for OTC use in the United States , FDA will inform the sponsor and other                                           |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1981-02-01 | To be considered, eight copies of the data and/or views on any marketed drug within the class must be submitted, preferably bound, indexed, and on standard sized paper (approximately 81/2 &#215; 11 inches).                                                                                                                                                                                                                                                                                                                                                            |
| 1981-07-27 | Information and data submitted under this section after July 27, 1981, shall include statements regarding each clinical investigation involving human subjects, from which the information and data are derived, that it either was conducted in compliance with the requirements for institutional review set forth in part 56 of this chapter, or was not subject to such requirements in accordance with &#167;&#167;&#8201;56.104 or 56.105, and that it was conducted in compliance with the requirements for informed consent set forth in part 50 of this chapter. |
| 1972-04-20 | (b) On and after April 20, 1972, a number of notices were published in the Federal Register concerning previously unpublished OTC drugs reviewed by the National Academy of Sciences-National Research Council Drug Efficacy Study Group.                                                                                                                                                                                                                                                                                                                                 |
| 1971-11-11 | (i) Certain Surgical Sutures (DESI 4725), published in the Federal Register of November 11, 1971 (36 FR 21612).                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1971-05-25 | (ii) Absorbable Dusting Powder (DESI 6264), published in the Federal Register of May 25, 1971 (36 FR 9475).                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1971-04-09 | (iii) Certain Insulin Preparations (DESI 4286), published in the Federal Register of April 9, 1971 (36 FR 6842).                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 1970-10-08 | (iv) Sulfo-Van Ointment (DESI 2230), published in the Federal Register of October 8, 1970 (35 FR 15860).                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1972-12-05 | (v) Antiperspirants and Deodorants Containing Neomycin Sulfate (DESI 11048) for which an order revoking provisions for certification or release was published in the Federal Register of December 5, 1972 (37 FR 25820) and has been stayed by the filing of objections.                                                                                                                                                                                                                                                                                                  |
| 1973-02-02 | (vi) Thorexin Cough Medicine (DESI 11160) for which a notice of opportunity for hearing was published in the Federal Register of February 2, 1973 (38 FR 3210).                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1972-09-30 | (vii) Antibiotic susceptibility discs (DESI 90235) for which an order providing for certain discs to be certified and removing provisions for certification of other discs was published in the Federal Register of September 30, 1972 (37 FR 20525) and has been stayed by the filing of objections notice of which was published in the Federal Register of March 15, 1973 (38 FR 7007).                                                                                                                                                                                |
| 1973-03-15 | (vii) Antibiotic susceptibility discs (DESI 90235) for which an order providing for certain discs to be certified and removing provisions for certification of other discs was published in the Federal Register of September 30, 1972 (37 FR 20525) and has been stayed by the filing of objections notice of which was published in the Federal Register of March 15, 1973 (38 FR 7007).                                                                                                                                                                                |
| 1970-10-24 | (i) Certain Sulfonamide-Decongestant Nasal Preparation (DESI 4850), for which notice of withdrawal of approval of new drug applications was published in the Federal Register of October 24, 1970 (35 FR 16605, 16606).                                                                                                                                                                                                                                                                                                                                                   |
| 1971-02-18 | (ii) Eskay's Theranates, containing strychnine, sodium, and calcium glycerophosphates, thiamine hydrochloride, alcohol, and phosphoric acid (DESI 2220), for which notice of withdrawal of approval of the new drug application was published in the Federal Register of February 18, 1971 (36 FR 3152).                                                                                                                                                                                                                                                                  |
| 1971-08-28 | (iii) The following topical drugs (DESI 1726), for which notice of withdrawal of new drug applications was published in the Federal Register of August 28, 1971 (36 FR 17368):                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (a) Rhulitol Solution, containing tannic acid, chlorobutanol, phenol, camphor, alum, and isopropyl alcohol.                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 1970-07-23 | (iv) Menacyl Tablets, containing aspirin, menadione, and ascorbic acid (DESI 6363), for which notice of withdrawal of approval of the new drug application was published in the Federal Register of July 23, 1970 (35 FR 11827).                                                                                                                                                                                                                                                                                                                                          |
| 1969-12-31 | (v) Curad Medicated Adhesive Bandage containing sulfathiazole (DESI 4964), for which notice of withdrawal of approval of the new drug application was published in the Federal Register of December 31, 1969 (34 FR 20441).                                                                                                                                                                                                                                                                                                                                               |
| 1970-07-03 | (vi) Drugs Containing Rutin, Quercetin, Hesperidin, or any Bioflavonoids (DESI 5960), for which notice of withdrawal of approval of new drug applications was published in the Federal Register of July 3, 1970 (35 FR 10872, 10873) and October 17, 1970 (35 FR 16332).                                                                                                                                                                                                                                                                                                  |
| 1970-10-17 | (vi) Drugs Containing Rutin, Quercetin, Hesperidin, or any Bioflavonoids (DESI 5960), for which notice of withdrawal of approval of new drug applications was published in the Federal Register of July 3, 1970 (35 FR 10872, 10873) and October 17, 1970 (35 FR 16332).                                                                                                                                                                                                                                                                                                  |
| 1970-10-17 | A further notice of opportunity for hearing with respect to the drugs covered by the October 17, 1970 Federal Register notice will be published at a later date.                                                                                                                                                                                                                                                                                                                                                                                                          |
| 1971-08-06 | (vii) Antibiotics in Combination with Other Drugs for Nasal Use (DESI 7561), for which an order revoking provision for certification was published in the Federal Register of August 6, 1971 (36 FR 14469) and confirmed in the Federal Register of October 28, 1971 (36 FR 20686).                                                                                                                                                                                                                                                                                       |
| 1971-10-28 | (vii) Antibiotics in Combination with Other Drugs for Nasal Use (DESI 7561), for which an order revoking provision for certification was published in the Federal Register of August 6, 1971 (36 FR 14469) and confirmed in the Federal Register of October 28, 1971 (36 FR 20686).                                                                                                                                                                                                                                                                                       |
| 1971-07-14 | (viii) Antibiotic Troches (DESI 8328), for which an order revoking provision for certification was published in the Federal Register of July 14, 1971 (36 FR 13089) and confirmed in the Federal Register of October 9, 1971 (36 FR 19695).                                                                                                                                                                                                                                                                                                                               |
| 1971-10-09 | (viii) Antibiotic Troches (DESI 8328), for which an order revoking provision for certification was published in the Federal Register of July 14, 1971 (36 FR 13089) and confirmed in the Federal Register of October 9, 1971 (36 FR 19695).                                                                                                                                                                                                                                                                                                                               |
| 1972-02-01 | (ix) Certain Drugs Containing Oxyphenisatin or Oxyphenisatin Acetate (DESI 10732), for which notices of withdrawal of approval of new drug applications were published in the Federal Register of February 1, 1972 (37 FR 2460), and March 9, 1973 (38 FR 6419).                                                                                                                                                                                                                                                                                                          |
| 1973-03-09 | (ix) Certain Drugs Containing Oxyphenisatin or Oxyphenisatin Acetate (DESI 10732), for which notices of withdrawal of approval of new drug applications were published in the Federal Register of February 1, 1972 (37 FR 2460), and March 9, 1973 (38 FR 6419).                                                                                                                                                                                                                                                                                                          |
| 1972-03-14 | (x) Curad Medicated Adhesive Bandage containing tyrothricin-nitrofurazone (DESI 6898), for which an order revoking provision for certification was published March 14, 1972 (37 FR 5294), and confirmed in the Federal Register of July 6, 1972 (37 FR 13254).                                                                                                                                                                                                                                                                                                            |
| 1972-07-06 | (x) Curad Medicated Adhesive Bandage containing tyrothricin-nitrofurazone (DESI 6898), for which an order revoking provision for certification was published March 14, 1972 (37 FR 5294), and confirmed in the Federal Register of July 6, 1972 (37 FR 13254).                                                                                                                                                                                                                                                                                                            |
| 1972-11-19 | (xi) Candette Cough Gel (DESI 11562), for which notice of withdrawal of approval of the new drug application was published in the Federal Register of November 19, 1972 (37 FR 25249).                                                                                                                                                                                                                                                                                                                                                                                    |
| 1972-11-29 | (xii) Certain OTC Multiple-Vitamin Preparations for Oral Use containing excessive amounts of vitamin D and/or vitamin A (DESI 97), for which notice of withdrawal of approval of the new drug applications was published in the Federal Register of November 29, 1972 (37 FR 25249).                                                                                                                                                                                                                                                                                      |
| 1973-02-02 | (xiii) Certain Sulfonamide-Containing Preparations for Topical Ophthalmic or Otic Use (DESI 368, for which a notice of withdrawal of approval was published in the Federal Register of February 2, 1973 (38 FR 3208).                                                                                                                                                                                                                                                                                                                                                     |
| 1967-02-02 | (xiv) Those parts of the publication entitled &#8220;Certain Mouthwash and Gargle Preparations&#8221; (DESI 2855) pertaining to Tyrolaris Mouthwash, containing tyrothricin, panthenol, and alcohol, for which an order revoking provision for certification was published in the Federal Register of February 2, 1967 (32 FR 1172) prior to the drug efficacy study implementation.                                                                                                                                                                                      |
| 1972-05-11 | (a) Before the publication in the Federal Register of an applicable proposed monograph, an OTC drug product that contains: (1) An active ingredient limited, on or after May 11, 1972, to prescription use for the indication and route of administration under consideration by an OTC advisory review panel, and not thereafter exempted from such limitation pursuant to &#167;&#8201;310.200 of this chapter, or                                                                                                                                                      |
| 1975-12-04 | (2) An active ingredient at a dosage level higher than that available in an OTC drug product on December 4, 1975, shall be regarded as a new drug within the meaning of section 201(p) of the act for which an approved new drug application is required.                                                                                                                                                                                                                                                                                                                 |
| 1972-05-11 | (b)(1) An OTC drug product that contains: (i) An active ingredient limited, on or after May 11, 1972, to prescription use for the indication and route of administration under consideration by an OTC advisory review panel, and not thereafter exempted from such limitation pursuant to &#167;&#8201;310.200 of this chapter, or                                                                                                                                                                                                                                       |
| 1975-12-04 | (ii) An active ingredient at a dosage level higher than that available in an OTC drug product on December 4, 1975, which ingredient and/or dosage level is classified by the panel in category I (conditions subject to &#167;&#8201;330.10(a)(6)(i)) shall be regarded as a new drug within the meaning of section 201(p) of the act for which an approved new drug application is required if marketed for OTC use prior to the date of publication in the Federal Register of a proposed monograph.                                                                    |
| 1972-05-11 | (c) An OTC drug product that contains: (1) An active ingredient limited, on or after May 11, 1972, to prescription use for the indication and route of administration under consideration by an OTC advisory review panel, and not thereafter exempted from such limitation pursuant to &#167;&#8201;310.200 of this chapter, or                                                                                                                                                                                                                                          |
|            |               (2) An active ingredient at a dosage level higher than that available in any OTC drug product on December 4, 1975, which ingredient and/or dosage level is classified by the panel in category II (conditions subject to &#167;&#8201;330.10(a)(6)(ii)), may be marketed only after:                                                                                                                                                                                                                                                                        |
| 1975-12-04 | (c) An OTC drug product that contains: (1) An active ingredient limited, on or after May 11, 1972, to prescription use for the indication and route of administration under consideration by an OTC advisory review panel, and not thereafter exempted from such limitation pursuant to &#167;&#8201;310.200 of this chapter, or                                                                                                                                                                                                                                          |
|            |               (2) An active ingredient at a dosage level higher than that available in any OTC drug product on December 4, 1975, which ingredient and/or dosage level is classified by the panel in category II (conditions subject to &#167;&#8201;330.10(a)(6)(ii)), may be marketed only after:                                                                                                                                                                                                                                                                        |
| 1972-05-11 | (d) An OTC drug product that contains: (1) An active ingredient limited, on or after May 11, 1972, to prescription use for the indication and route of administration under consideration by an OTC advisory review panel, and not thereafter exempted from such limitation pursuant to &#167;&#8201;310.200 of this chapter, or                                                                                                                                                                                                                                          |
|            |               (2) An active ingredient at a dosage level higher than that available in any OTC drug product on December 4, 1975, which ingredient and/or dosage level is classified by the panel in category III (conditions subject to &#167;&#8201;330.10(a)(6)(iii)), may be marketed only after:                                                                                                                                                                                                                                                                      |
| 1975-12-04 | (d) An OTC drug product that contains: (1) An active ingredient limited, on or after May 11, 1972, to prescription use for the indication and route of administration under consideration by an OTC advisory review panel, and not thereafter exempted from such limitation pursuant to &#167;&#8201;310.200 of this chapter, or                                                                                                                                                                                                                                          |
|            |               (2) An active ingredient at a dosage level higher than that available in any OTC drug product on December 4, 1975, which ingredient and/or dosage level is classified by the panel in category III (conditions subject to &#167;&#8201;330.10(a)(6)(iii)), may be marketed only after:                                                                                                                                                                                                                                                                      |
| 1972-05-11 | (e) This section applies only to conditions under consideration as part of the OTC drug review initiated on May 11, 1972, and evaluated under the procedures set forth in &#167;&#8201;330.10.                                                                                                                                                                                                                                                                                                                                                                            |
| 2018-03-01 | (vii) The submission includes data or information relevant for making a GRASE determination marked as confidential without a statement that the information may be released to the public.                                                                                                                                                                                                                                                                                                                                                                                |
| 2014-11-27 | (2) A non-sunscreen active ingredient or combination of non-sunscreen active ingredients, and other conditions for such ingredients submitted in a TEA under &#167;&#8201;330.14 before November 27, 2014, subject to section 586F(a)(1)(C) of the Federal Food, Drug, and Cosmetic Act.                                                                                                                                                                                                                                                                                  |


